Wedbush lifts BEAM target to $33 on Outperform
Alpha Vantage · TradingView · · AI-summarised by FinFlash
Wedbush has reaffirmed its "Outperform" rating for Beam Therapeutics (BEAM) and increased its price target to $33 from $30, indicating a 10.0% rise. This new price target suggests an upside of 31.2% from the stock's closing price of $25.15 on November 10. Other analysts have recently issued price targets ranging from $30 to $80 for Beam Therapeutics.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.